Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FI5C
|
|||
| Former ID |
DCL000558
|
|||
| Drug Name |
MEDI-528
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1], [2], [3], [4], [5] | |
| Company |
MedImmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-9 (IL9) | Target Info | Inhibitor | [6] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Asthma | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| WikiPathways | TCR Signaling Pathway | |||
| IL-9 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00507130) A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma | |||
| REF 2 | ClinicalTrials.gov (NCT00968669) A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT00590720) A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma | |||
| REF 4 | ClinicalTrials.gov (NCT00394654) A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma | |||
| REF 5 | ClinicalTrials.gov (NCT00483041) A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528 | |||
| REF 6 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.